Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.82 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.78 |
| ▸ | PDE2A | O00408 | 1/20 | 0.78 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.78 |
| ▸ | PDE6D | O43924 | 1/20 | 0.78 |
| ▸ | PDE8A | O60658 | 1/20 | 0.78 |
| ▸ | PDE9A | O76083 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | PDE6A | P16499 | 1/20 | 0.78 |
| ▸ | PDE6G | P18545 | 1/20 | 0.78 |
| ▸ | PDE4A | P27815 | 1/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | PDE6B | P35913 | 1/20 | 0.78 |
| ▸ | PDE6C | P51160 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14836633 | 0.97 | PDE5A (0.78) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL5008153 | 0.93 | PDE5A (0.86) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL14946627 | 0.91 | PDE5A (0.89) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL7902595 | 0.91 | PDE5A (0.83) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL6096363 | 0.91 | PDE5A (0.87) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL30848678 | 0.90 | PDE5A (0.95) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL5128871 | 0.90 | PDE5A (0.81) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL5008158 | 0.89 | PDE5A (0.81) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL29144808 | 0.88 | PDE5A (0.94) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5683880 | 0.88 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315729-B1 | COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PROD QUIMICOS FARM (BR) | 2008-01-09 | — | — | EP | disclosed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999064033-A9 | PHOSPHODIESTERASE-V MODULATOR DRUGS AND THEIR USES | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | PDE5A 1814/4885PDE3B 2025/4885PDE3A 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.